Accès gratuit
Numéro
Med Sci (Paris)
Volume 26, Numéro 4, Avril 2010
Page(s) 385 - 390
Section M/S revues
DOI https://doi.org/10.1051/medsci/2010264385
Publié en ligne 15 avril 2010
  1. Festa A, Williams K, D’Agostino R Jr, et al. The natural course of beta-cell function in nondiabetic and diabetic individuals: the insulin resistance atherosclerosis study. Diabetes 2006; 55 : 1114–20.
  2. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116 : 1802–12.
  3. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002; 1585 : 202–12.
  4. Girard J. Rôle des acides gras libres dans la sécrétion et l’action de l’insuline : mécanismes de la lipotoxicité. Med Sci (Paris) 2003; 19 : 827–33.
  5. Ishikawa M, Iwasaki Y, Yatoh S, et al. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J Lipid Res 2008; 49 : 2524–34.
  6. Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007; 56 : 2328–38.
  7. Brunham LR, Kruit JK, Pape TD, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13 : 340–7.
  8. Efanov AM, Sewing S, Bokvist K, Gromada J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 2004; 53 (suppl 3) : S75–8.
  9. Gerin I, Dolinsky VW, Shackman JG, et al. LXRbeta is required for adipocyte growth, glucose homeostasis, and beta cell function. J Biol Chem 2005; 280 : 23024–31.
  10. McNeish J, Aiello RJ, Guyot D, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 2000; 97 : 4245–50.
  11. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368 : 1096–105.
  12. Grupping AY, Cnop M, Van Schravendijk CF, et al. Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 1997; 138 : 4064–8.
  13. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002; 143 : 3449–53.
  14. Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278 : 18368–75.
  15. Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007; 50 : 1304–14.
  16. Okajima F, Kurihara M, Ono C, et al. Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta 2005; 1687 : 173–80.
  17. Rutti S, Ehses JA, Sibler RA, et al. Low and high-density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic beta cells. Endocrinology 2009; 150 : 4521–30
  18. Salaun C, James DJ, Chamberlain LH. Lipid rafts and the regulation of exocytosis. Traffic 2004; 5 : 255–64.
  19. Lang T. SNARE proteins and “membrane rafts”. J Physiol 2007; 585 : 693–8.
  20. Xia F, Gao X, Kwan E, et al. Disruption of pancreatic beta-cell lipid rafts modifies Kv2.1 channel gating and insulin exocytosis. J Biol Chem 2004; 279 : 24685–91.
  21. Ohara-Imaizumi M, Nishiwaki C, Kikuta T, et al. Site of docking and fusion of insulin secretory granules in live MIN6 beta cells analyzed by TAT-conjugated anti-syntaxin 1 antibody and total internal reflection fluorescence microscopy. J Biol Chem 2004; 279 : 8403–8.
  22. Takahashi N, Hatakeyama H, Okado H, et al. Sequential exocytosis of insulin granules is associated with redistribution of SNAP25. J Cell Biol 2004; 165 : 255–62.
  23. Vikman J, Jimenez-Feltstrom J, Nyman P, et al. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J 2009; 23 : 58–67.
  24. Xia F, Xie L, Mihic A, Gao X, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008; 149 : 5136–45.
  25. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 2001; 103 : 357–62.
  26. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 20 ; 359 : 2195–207.
  27. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375 : 735–42.
  28. Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006; 13 : 329–35.
  29. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J 1993; 295 : 31–40.
  30. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999; 126 : 1205–13.
  31. Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 2008; 118 : 403–8.
  32. Schaefer EJ, Brousseau ME, Diffenderfer MR, et al. Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis 2001; 159 : 231–6.
  33. Villarreal-Molina MT, Guilar-Salinas CA, Rodriguez-Cruz M, et al. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes 2007; 56 : 1881–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.